Association of ITPA polymorphism with outcomes of peginterferon-α plus ribavirin combination therapy

Table 1 Baseline characteristics of patients

Baseline characteristics	ITPA polymorphism (rs1127354)		P value
	CA/AA (n = 37)	CC (n = 83)
Age (yr)	61 ± 8	59 ± 11	NS
Gender: male/female	18/19	37/46	NS
HCV RNA (log IU/mL)	6.2 ± 0.6	5.9 ± 0.5	NS
Hemoglobin (g/dL)	13.4 ± 1.5	13.8 ± 1.7	NS
WBC (× 103/μL)	4.7 ± 1.2	5.0 ± 1.5	NS
Platelet (× 104/μL)	18.0 ± 6.0	18.0 ± 7.0	NS
AST (IU/L)	56.8 ± 34.9	58.2 ± 42.3	NS
ALT (IU/L)	65.5 ± 40.0	68.4 ± 56.8	NS
GGT (IU/L)	56.1 ± 52.3	55.3 ± 49.4	NS
AFP (ng/mL)	5.3 ± 4.0	24.2 ± 61.8	NS
Staging: F1,2/F3,4	19/16	49/27	NS
IL28B: TT/TG + GG	29/8	53/30	NS

ITPA: Inosine triphosphatase; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; GGT: γ-glutamyl transpeptidase; AFP: α-fetoprotein; NS: Not significant; HCV: Hepatitis C virus; IL28B: Interleukin 28B.